US-based Aesthera today announced that the Food and Drug Administration has cleared its photopneumatic system for the treatment of vascular and pigmented lesions, and permanent hair reduction.
Many former Lumenis executives have invested in Aesthera including former CEO Yacha Sutton, and former directors Zeev Tadmor and Amnon Harari. Aesthera CEO Alon Maor was the former VP of Lumenis's aesthetic unit. Other investors include Adams Street Partners and Med Ventures.
Maor said, “FDA clearance of photopneumatic (PPx) therapy is a significant milestone for the nearly $25.5 billion U.S. cosmetic procedure market because it is the first treatment that is actually no pain, more gain".
With FDA clearance, Aesthera will begin taking orders for the PPx system from qualified physicians immediately.
Aesthera stated that its PPx therapy is a painless, safer light based therapy to treat sun damaged and aging skin. PPx therapy is a combination of pneumatic energy (pressure) and broadband light. Unlike existing treatment alternatives, patients do not need to undergo time consuming pre-treatment procedures such as applying topical numbing agents or cooling gels. Immediately after the procedure, patients are ready to resume their normal activities.
According to the American Society for Aesthetic Plastic Surgery, 11.9 million cosmetic surgical and non-surgical procedures were performed on Americans in 2004 to combat the appearance of aging.
Published by Globes [online], Israel business news - www.globes.co.il - on Tuesday, May 03, 2005